

# PCT

## POWER OF ATTORNEY

(for an international application filed under the Patent Cooperation Treaty)

(PCT Rule 90.4)

The undersigned applicant(s) (Names should be indicated as they appear in the request):

**PADLAN, Eduardo A.**  
4006 Simms Drive  
Kensington, Maryland 20895  
United States of America

hereby appoints the following persons as :

☒ agents

☐ common representative

### Name and address

(Family name followed by given name; for a legal entity, full official designation. The address must include a postal code and name of country.)

Astor, Marlene; Dixon, Jonathan V.; Finley, Stephen L.; Ferguson, Steven; Haight, James C.; Joyce, Catherine M.; Kim, John Peter; Pontzer, Norbert; Rodriguez, Richard U.; Rucker, Susan S.; Sadowski, David R.; Shmilovich, Michael A.; and Spiegel, Jack; all of the National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite #325, Rockville, Maryland 20852, U.S.A., acting under authority of the Department of Health and Human Services, Government of the United States of America; and

Bunker, Gillian L.; Caldwell, Lisa M.; Carlson, Anne; Haendler, Jeffrey B.; Harding, Tanya M.; Jones, Michael D.; Maurer, Gregory L.; Noonan, William D.; Polley, Richard J.; Rupert, Wayne W.; Rybak, Sheree L.; Siegel, Susan Alpert; Slater, Stacey C.; Stephens Jr., Donald L.; Stuart, John W.; Wight, Stephen A.; and Young, Travis; all of the firm of Klarquist Sparkman, LLP, Suite 1600, 121 S.W. Salmon Street, Portland, Oregon, 97204, U.S.A.

to represent the undersigned before



all the competent International Authorities



the International Searching Authority only



the International Preliminary Examining Authority only

in connection with the international application identified below:


Title of the invention: HUMANIZED ANTI-TAG 72 CC49 FOR DIAGNOSIS AND THERAPY OF HUMAN TUMORS

Applicant's or agent's file reference: 4239-66176

International application number (if already available):

filed with the following Office United States Patent and Trademark Office as receiving Office and to make or receive payments on behalf of the undersigned

Signature of the applicant(s) (where there are several applicants each of them must sign; next to each signature, indicate the name of the person signing and the capacity in which the person signs, if such capacity is not obvious from reading the request or this power)

  
\_\_\_\_\_  
Eduardo A. Padlan  
Applicant/Inventor

6/24/03  
\_\_\_\_\_  
Date

# PCT

## POWER OF ATTORNEY

(for an international application filed under the Patent Cooperation Treaty)

(PCT Rule 90.4)

The undersigned applicant(s) (Names should be indicated as they appear in the request):

**KASHMIRI, Syed V.S.**  
11541 Brandy Hall Lane  
Gaithersburg, Maryland 20878  
United States of America

hereby appoints the following persons as :



agents



common representative

### Name and address

(Family name followed by given name; for a legal entity, full official designation. The address must include a postal code and name of country.)

Astor, Marlene; Dixon, Jonathan V.; Finley, Stephen L.; Ferguson, Steven; Haight, James C.; Joyce, Catherine M.; Kim, John Peter; Pontzer, Norbert; Rodriguez, Richard U.; Rucker, Susan S.; Sadowski, David R.; Shmilovich, Michael A.; and Spiegel, Jack; all of the National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite #325, Rockville, Maryland 20852, U.S.A., acting under authority of the Department of Health and Human Services, Government of the United States of America; and

Bunker, Gillian L.; Caldwell, Lisa M.; Carlson, Anne; Haendler, Jeffrey B.; Harding, Tanya M.; Jones, Michael D.; Maurer, Gregory L.; Noonan, William D.; Polley, Richard J.; Rupert, Wayne W.; Rybak, Sheree L.; Siegel, Susan Alpert; Slater, Stacey C.; Stephens Jr., Donald L.; Stuart, John W.; Wight, Stephen A.; and Young, Travis; all of the firm of Klarquist Sparkman, LLP, Suite 1600, 121 S.W. Salmon Street, Portland, Oregon, 97204, U.S.A.

to represent the undersigned before



all the competent International Authorities



the International Searching Authority only



the International Preliminary Examining Authority only

in connection with the international application identified below:

Title of the invention: HUMANIZED ANTI-TAG 72 CC49 FOR DIAGNOSIS AND THERAPY OF HUMAN TUMORS

Applicant's or agent's file reference: 4239-66176

International application number (if already available):

filed with the following Office United States Patent and Trademark Office as receiving Office and to make or receive payments on behalf of the undersigned

Signature of the applicant(s)

(where there are several applicants each of them must sign; next to each signature, indicate the name of the person signing and the capacity in which the person signs, if such capacity is not obvious from reading the request or this power)

S. V. S. Kashmiri  
Syed V.S. Kashmiri  
Applicant/Inventor

6-18-03  
Date

# PCT

## POWER OF ATTORNEY

(for an international application filed under the Patent Cooperation Treaty)

(PCT Rule 90.4)

The undersigned applicant(s) (Names should be indicated as they appear in the request):

**SCHLOM, Jeffrey**  
10301 Sorrel Avenue  
Potomac, Maryland 20854  
United States of America

hereby appoints the following persons as :

☒ agents

☐ common representative

**Name and address**

(Family name followed by given name; for a legal entity, full official designation. The address must include a postal code and name of country.)

Astor, Marlene; Dixon, Jonathan V.; Finley, Stephen L.; Ferguson, Steven; Haight, James C.; Joyce, Catherine M.; Kim, John Peter; Pontzer, Norbert; Rodriguez, Richard U.; Rucker, Susan S.; Sadowski, David R.; Shmilovich, Michael A.; and Spiegel, Jack; all of the National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite #325, Rockville, Maryland 20852, U.S.A., acting under authority of the Department of Health and Human Services, Government of the United States of America; and

Bunker, Gillian L.; Caldwell, Lisa M.; Carlson, Anne; Haendler, Jeffrey B.; Harding, Tanya M.; Jones, Michael D.; Maurer, Gregory L.; Noonan, William D.; Polley, Richard J.; Rupert, Wayne W.; Rybak, Sheree L.; Siegel, Susan Alpert; Slater, Stacey C.; Stephens Jr., Donald L.; Stuart, John W.; Wight, Stephen A.; and Young, Travis; all of the firm of Klarquist Sparkman, LLP, Suite 1600, 121 S.W. Salmon Street, Portland, Oregon, 97204, U.S.A.

to represent the undersigned before

☒ all the competent International Authorities

☐ the International Searching Authority only

☐ the International Preliminary Examining Authority only

in connection with the international application identified below:

**Title of the invention:** HUMANIZED ANTI-TAG 72 CC49 FOR DIAGNOSIS AND THERAPY OF HUMAN TUMORS

**Applicant's or agent's file reference:** 4239-66176

**International application number (if already available):**

filed with the following Office United States Patent and Trademark Office as receiving Office and to make or receive payments on behalf of the undersigned

**Signature of the applicant(s)** (where there are several applicants each of them must sign; next to each signature, indicate the name of the person signing and the capacity in which the person signs, if such capacity is not obvious from reading the request or this power)

  
Jeffrey Schlom  
Applicant/Inventor

6-25-03  
Date

# PCT

## GENERAL POWER OF ATTORNEY

(for an international application filed under the Patent Cooperation Treaty)

(PCT Rule 90.4)

The undersigned applicant:

**THE GOVERNMENT OF THE UNITED STATES OF AMERICA**, as represented by the Secretary, Department of Health and Human Services.

hereby appoints the following persons as :

☒ agent

☐ common representative

### Name and address

(Family name followed by given name: for a legal entity, full official designation. The address must include a postal code and name of country.)

Haight, James C.; Sadowski, David R.; Benson, Robert; Spiegel, Jack; Rucker, Susan S.; Finley, Stephen L.; Ferguson, Steven; Kim, John Peter; Pontzer, Norbert; Rodriguez, Richard U.; Shinn, Marlene; Berkley, Dale; and Joyce, Catherine M. all of the National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite #325, Rockville, Maryland 20852, U.S.A., acting under authority of the Department of Health and Human Services, Government of the United States of America; and

Bunker, Gillian L.; Caldwell, Lisa M.; Carlson, Anne; Haendler, Jeffrey B.; Harding, Tanya M.; Jones, Michael D.; Maurer, Gregory L.; Mirho, Charles A.; Noonan, William D.; Polley, Richard J.; Rupert, Wayne W.; Rybak, Sheree L.; Siegel, Susan Alpert; Slater, Stacey C.; Stephens Jr., Donald L.; Stuart, John W.; Zastrow, Devon J. all of the firm of Klarquist Sparkman, LLP, Suite 1600, 121 S.W. Salmon Street, Portland, Oregon, 97204, U.S.A.


as agents to represent the undersigned before all the competent International Authorities in connection with all international applications filed by the undersigned with the United States Patent & Trademark Office as Receiving Office and to make or receive payments on behalf of the undersigned.

Address all correspondence to :

William D. Noonan, M.D.  
KLARQUIST SPARKMAN, LLP  
One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, OR 97204-2988  
(503) 226-7391  
(503) 228-9446 – Facsimile

The National Institutes of Health Office of Technology Transfer has been duly delegated responsibility for such patent matters under the authority of the Department of Health and Human Services Secretary Louis W. Sullivan's memorandum of May 21, 1991, appearing in the Friday June 7, 1991 Federal Register Notices at Volume 56, Number 100, pages 26418-26419. The undersigned is authorized to exercise such authority in this matter.

By:

  
James C. Haight  
Reg No: 25,588  
For: Mark Rohrbaugh, Acting Director  
Office of Technology Transfer  
National Institutes of Health  
6011 Executive Blvd., Suite 325  
Rockville, Maryland 20852 USA  
Telephone: (301) 496-7056  
Facsimile: (301) 402-0220

Date: 6 FEB 2002



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health  
Office of Technology Transfer  
8011 Executive Boulevard, Suite 325  
Rockville, Maryland 20862

DATE: October 9, 2001

TO: Commissioner for Patents  
U.S. Patent and Trademark Office

FROM: Acting Director, Office of Technology Transfer (OTT)  
National Institutes of Health

SUBJECT: Delegation of Authority for Certain Patent Administration and Prosecution Activities

Effective this date and acting under the authority set forth in DHHS Secretary Louis W. Sullivan's May 21, 1991 memorandum appearing in the Friday, June 7, 1991 Federal Register Notices at Volume 56, Number 110, pages 26418-26419 (copy attached), I authorize James C. Haight, (Reg. No. 25,588); David R. Sadowski, (Reg. No. 32,808); Robert Benson, (Reg. No. 33,622); Jack Spiegel, (Reg. No. 34,477); Susan S. Rucker, (Reg. No. 35,762); Stephen Finley, (Reg. No. 36,357); Steven Ferguson, (Reg. No. 38,488); John Peter Kim, (Reg. No. 38,514); Norbert Pontzer, (Reg. No. 40,777); Richard U. Rodriguez, (Reg. No. 45,980); Marlene Shinn, (Reg. No. 46,005); Berkley, Dale, (Reg. No. 42,319) and Catherine M. Joyce, (Reg. No. 40,668) to exercise full authority in United States or International patents or patent applications in which the Government of the United States of America, as represented by the Secretary, Department of Health and Human Services is an applicant or has an ownership interest with respect to the following:

- Signing original, associate, or substitute powers of attorney before the U.S. or International Authorities;

- Signing Request Forms, Demand Forms, and other documents filed in applications before the International Authorities;

- Signing assignee's consent to changes in inventorship;

Signing papers required from an assignee in connection with an application for Reissue and/or Reexamination of a patent;

Signing terminal disclaimers including, but not limited to, terminal disclaimers to obviate obviousness-type double patenting rejections; and

Signing all documents before the United States Patent and Trademark Office, either as the U.S. National Office or as a designated Receiving Office under the Patent Cooperation Treaty that can be signed by an assignee in patent matters.

Mark L. Rohrbaugh, Ph.D., J.D.

Attachment

cc: OTT Staff

Best Available Copy

### F.N.B. Corporation, et al; Acquisitions of Companies Engaged in Permissible Nonbanking Activities

The organizations listed in this notice have applied under § 225.23(a)(2) or (f), of the Board's Regulation Y (12 CFR 225.23(a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.23(a) of Regulation Y (12 CFR 225.23(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted through bank holding companies.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated for the application or the office of the Board of Governors not later than June 28, 1991.

**1. Federal Reserve Bank of Cleveland** (John J. Wileed, Jr., Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101.

**F.N.B. Corporation, Hummel, Pennsylvania** to acquire Regency Consumer Discount Company, Inc., Scranton, Pennsylvania, and thereby engage in lending and acquiring nonbanking assets pursuant to § 225.25(b)(1); and in the sale of credit life, accident, and health insurance pursuant to § 225.25(b)(3) of the Board's Regulation Y.

**2. Federal Reserve Bank of Atlanta** (Robert E. Heck, Vice President) 104 Marietta Street, NW, Atlanta, Georgia 30303.

**1. Evergreen Bancshares, Inc., Tallahassee, Florida** to establish Evergreen Federal Interim Savings Bank, Tallahassee, Florida (Interim Bank), to acquire certain assets and assume certain liabilities of the Tallahassee, Florida branch office of Anchor Savings Bank, PSB, Hewlett, New York, pursuant to section 4(c)(8) of the Bank Holding Company Act and the Oaker Amendment of FIRREA, and to facilitate the merger of Interim Bank with and into Evergreen's subsidiary bank, Guaranty National Bank of Tallahassee, Tallahassee, Florida.

**2. First State Corporation, Albany, Georgia** to acquire Randolph Federal Savings & Loan Association, Cuthbert, Georgia (Randolph Federal), pursuant to section 4(c)(8) of the Bank Holding Company Act. Applicant also proposes to merge Randolph Federal with and into its bank subsidiary, First State Bank & Trust Company, Albany, Georgia, pursuant to the Oaker Amendment of FIRREA.

Board of Governors of the Federal Reserve System, June 3, 1991.

Jennifer J. Johnson

Associate Secretary of the Board

(FR Doc. 91-13477 Filed 6-6-91; 8:45 am)  
GALING CODE 32101P

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Office of the Secretary

Office of the General Counsel  
Statement of Organization, Functions  
and Delegations of Authority

Part A, chapter AC (Office of the General Counsel, Office of the Secretary) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (38 FR 17033, June 28, 1973, as amended most recently in pertinent part at 55 FR 17500, April 25, 1990), and part H, chapter HN (National Institutes of Health, Public Health Service) (40 FR 22850, May 27, 1975, as amended most recently in pertinent part at 55 FR 25303, August 29, 1990), are amended to:

(1) Delete the Department Patent Officer (AC25) and transfer patent administration and prosecution responsibilities from this Officer to the Office of Technology Transfer (HNA432), Office of Intramural Affairs (HNA43), Office of Intramural Research (HNA4), Office of the Director (HNA).

National Institutes of Health (NIH), Public Health Service (H). Patent administration and prosecution activities will be consolidated with patent licensing functions within a single NIH organizational entity in order to improve program and resource management; and

(2) Retain patent legal services of the Department Patent Officer (AC35) in the Public Health Division (AC22a), Office of the General Counsel, Office of the Secretary, and update the functional statement for the Public Health Division to reflect its responsibilities more accurately.

#### Office of the Secretary

Under Chapter AC, Office of the General Counsel, Sections AC35 (Department Patent Officer) and AC22a (Public Health Division), delete the titles and statements in their entirety and substitute the following:

**Public Health Division (AC22a).** The Public Health Division shall provide legal services, including patent legal services, for programs administered by the Public Health Service (except the Food and Drug Administration), e.g., the Office of the Assistant Secretary for Health, and the agencies and offices of the Public Health Service (other than FDA), including the Office of Technology Transfer and the Patent Policy Board.

#### Public Health Service

Under Chapter HN, National Institutes of Health, Section HNA, Office of the Director, Office of Intramural Affairs (HNA43), add the following title and statement:

**Office of Technology Transfer (HNA432).** (1) Develops policy and procedures for NIH, ADAMHA, and CDC to follow for the implementation of Cooperative Research and Development Agreements (CRADAs), patent licenses, and other technology transfers; (2) implements Patent Policy Board decisions and policies; (3) drafts, negotiates, and periodically revises model forms and agreements; (4) provides advice to ICs on problem licenses and agreements; (5) develops policy statements on various technology transfer issues such as conflicts of interest; (6) tracks the OTT budget and prepares an annual status report to the NIH Office of the Director; (7) provides coordination and management of goals, functions, and operations of the Technology Management Branch, Technology Licensing Branch, and the Technology Transfer Coordination Branch; (8) coordinates and provides planning and liaison support for

international CRADAs and technology transfers; (8) creates and implements special programs relating to technology transfer by State and local governments and universities; (10) drafts and presents Congressional testimony, and drafts technology transfer-related responses to other Congressional inquiries; (11) provides operational management activities; (12) assists the Office of the General Counsel (OGC) in evaluating patent-related litigation matters; (13) in consultation with OGC and the involved agency component, as appropriate, negotiates settlements on contested matters with licensees or other parties involved with NIH, ADAMHA, and CDC in technology transfer or utilization matters; (14) represents the NIH, ADAMHA, and CDC in technology transfer or utilization matters; (15) represents the above agencies at a variety of professional conferences and other public forums; (16) investigates special issues; (17) evaluates the need for and develops new programs in technology management and technology transfer for the above agencies; (18) develops licensing strategies for NIH/ADAMHA/CDC intramural and CRADA inventions; (19) negotiates licenses and other technology transfers; (20) works with scientist inventors, contract attorneys and others in preparing patent applications and prosecuting these applications at the Patent Office level; (21) handles infringements in consultation with the OGC at the Patent Office level; and (22) makes recommendations to the OCC for referral of matters to the Department of Justice.

Dated: May 31, 1991.

John W. Sullivan.

Secretary.

(FR Doc. 91-11113 Filed 6-5-91; 8:45 am)

100-100000-100000

#### Agency for Health Care Policy and Research; Establishment

Pursuant to the Federal Advisory Committee Act, Public Law 92-463 (6 U.S.C. appendix 2), the Administration, Agency for Health Care Policy and Research (AHCPR), announces the establishment of the following advisory committee.

**Designation:** Employer-Based Health Insurance Advisory Committee.

**Purpose:** The purpose of the Committee is to advise and make recommendations to the Secretary, OHS, and the Administrator, AHCPR, with regard to the awarding of a proposed contract designed to provide AHCPR with a comprehensive policy-oriented

report that describes the current status and problems of employer-based health insurance and evaluates options for improving, reforming or replacing this system.

**Function:** The Committee shall review and make recommendations to the Administrator on the scientific and technical merit of proposals received in response to the Request for Proposal entitled Employer-Based Health Insurance.

**Structure:** The Committee shall consist of up to three members, including the Chair, who will serve for the duration of the Committee. No member may be an officer or employee of the Federal Government. Members and Chair shall be selected by the Administrator, AHCPR, from individuals with appropriate expertise and experience in health services research, including but not limited to the areas of health economics, utilization and costs of health insurance, research evaluation and dissemination, and assessment of the impact of the dissemination of research.

Notwithstanding section 14(a) of the Federal Advisory Committee Act, the Committee shall continue in existence until otherwise provided by law or upon a determination by the Administrator, AHCPR, or his delegate, that the purpose of the Committee has been accomplished.

Dated: May 31, 1991.

J. James Callahan.

Administrator, Agency for Health Care Policy and Research.

(FR Doc. 91-13564 Filed 6-5-91; 8:45 am)

100-100000-100000

#### Administration for Children and Families

Formis Submitted to the Office of Management and Budget for Clearance

The Administration for Children and Families will publish on Fridays information collection packages submitted to the Office of Management and Budget (OMB) for clearance, in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). This collection package is being submitted for expedited review in compliance with 5 CFR 1320.16.

(For a copy of a package, call the SSA, Report Clearance Officer 202-701-5801.)

**Plan for the Child Care and Development Block Grant, Form ACF-118-NEW.**—The information contained in the Block grant plan is to determine whether the plan can be approved for

Block Grant funding, as required in section 6582(d) of the Budget Reconciliation Act; and to determine if the lead agency is operating in accordance with its plan where issues of compliance arise. **Respondents:** States or local governments; **Number of Responses:** 25; **Frequency of Response:** Biennially (after initial submission); **Average Burden per Response:** 60 hours; **Estimated Annual Burden:** 12,750 hours.

**OMB Desk Clearance Officer:** Laura Olliver.

Consideration will be given to comments and suggestions received within 10 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the appropriate OMB Desk Officer designated above at the following address:

OMB Reports Management Branch, New Executive Office Building, room 3201, 725 17th Street, NW., Washington, DC 20503.

Dated: May 31, 1991.

Nobert B. Marr.

Associate Administrator, Office of Management and Information Systems.

**Draft Plan For The Child Care & Development Block Grant**

(Grantee) \_\_\_\_\_  
for the period \_\_\_\_\_  
through \_\_\_\_\_

#### Table of Contents

- Section 1 Assurances
- Section 2 Lead Agency Responsibilities
  - 2.1 Administration
  - 2.2 Consultation
  - 2.3 Coordination of Services
  - 2.4 Public Hearing Process
  - 2.5 Public-Private Partnerships
- Section 3 Child Care Services (75% of Block Grant Funds)
  - 3.1 Description of Services and Process to Receive Such Services
  - 3.2 Description of Activities to Improve the Availability and Quality of Child Care
  - 3.3 Localities
  - 3.4 Basis for Allocating Funds for Such Services and Activities
  - 3.5 Eligibility Criteria and Priority Rules for Children
  - 3.6 Criteria for Awarding Grants and Contracts
  - 3.7 Eligibility Terminology
  - 3.8 Tribal Eligibility Criteria
- Section 4 Activities to Improve the Quality of Child Care and to Increase the Availability of Early Childhood Development Programs and Before- and After-School Care Services (25% of Block Grant Funds)
  - 4.1 Description of Activities
  - 4.2 Localities

Best Available Copy